**Rob, Jim, anyone else interested, I think I may have found us a ringer here, but you guys are way better than I reading on chemo. I still do visuals (charts) and this chart has a beautiful up channel just forming. Also, read my note about the 20 x 50 EMA “Kisses”. **
In the next three trading days, if $ADMA does not move upward, I’d be might surprised.
This is what I hope Rob, Jim, Peter, Ron, and Amusekind (give us your real name, mysterious female) will look over more and maybe hit biopharmcatalyst.com to view their pipelines.
**Right now two problems: Chemo brain short attention span AND fingers are like stiff sausages with no fluid in my joints (philanges? sp?), my wrists, and my elbows. This chemo exacted the same drying out of joints last week too, same joints I just named. **
Anyway, enough from this Big Crybaby, help me out. Check over this article. Earnings came in yesterday and it’s the latter half of 2023 outlook which excites me.
Things you can help us learn: What is their number one drug and what is it used for?
What’s in the pipeline?
Is it overseas yet?
Do we have any drugs awaiting for the PDUFA?
Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase*
Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021*
Full Year 2023 Total Revenues are Expected to be $210 Million or More, Representing Approximately 40% Year-Over-Year Growth Rate*
First-Time Positive EBITDA Expected During Second Half of 2023
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) – ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be approximately $49-50 million, an increase of approximately 89% over the fourth quarter of 2021, and full year 2022 preliminary, unaudited revenue of approximately $153-$154 million, an increase of approximately 90% over full year 2021.
“ADMA has successfully demonstrated its position as the fastest growing provider of immunoglobulin in the US market,” said Adam Grossman, President and Chief Executive Officer of ADMA. “Enabled by the milestone achievements across our organization, we believe we have a clear line of sight to durable revenue growth as well as rapidly approaching profitability. With the investment phase of ADMA’s business cycle concluding and the business’ foundation solidly established, we have gained confidence in the Company’s pathway to achieve positive EBITDA during the second half of 2023 as well as our conviction in the ultimate revenue and profitability potential ADMA’s asset base is expected to generate thereafter. In 2023, building on the established momentum, our organization is unified and unwavering in our focus on delivering on all strategic and financial objectives.”
ADMA currently anticipates full year 2023 total revenues of $210 million or more. This outlook is based on our expectations that the U.S. immune globulin market will continue to grow and there will be further share gains for ADMA’s commercial products within this end-market landscape. A favorably evolving product mix coupled with the realization of supply chain and manufacturing efficiencies are anticipated to drive further margin improvements throughout the year. As a result, ADMA anticipates generating first-time positive EBITDA during the second half of 2023.